Khiron Life Sciences closes sale of its European business

1 minute read
17 November 2023

On November 17, 2023, Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) ("Khiron") announced that it had completed the sale of its European subsidiaries, being Khiron Europe GmbH, Zerenia Clinics Limited, PharmaDrug Production GmbH, Khiron Life Sciences UK Limited and Khiron Life Sciences Spain SL to 2518542 Alberta Ltd., a company controlled by Avonlea-Drewry Holdings Inc., for an aggregate base purchase price of $3,000,000.

Khiron is a leading global medical cannabis company with core operations in Latin America. Leveraging wholly owned medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and focus on creating access to drive prescriptions and brand loyalty with patients worldwide.

Gowling WLG advised Khiron with respect to this sale with a team that included Peter Simeon, Josh Almario, Ashley Andaya, James Stewart and Jevaughn Johnson.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.